Senti Biosciences, Inc. (NASDAQ:SNTI) Short Interest Up 95.5% in January

Senti Biosciences, Inc. (NASDAQ:SNTI) was the target of a large increase in short interest in January. As of January 31st, there was short interest totalling 103,800 shares, an increase of 95.5% from the January 15th total of 53,100 shares. Based on an average daily trading volume, of 2,240,000 shares, the days-to-cover ratio is currently 0.0 days. Currently, 3.4% of the shares of the stock are sold short.

Analyst Upgrades and Downgrades

Separately, Chardan Capital reiterated a “buy” rating and set a $10.00 price objective on shares of Senti Biosciences in a research note on Monday, December 2nd.

Institutional Trading of Senti Biosciences

An institutional investor recently bought a new position in Senti Biosciences stock. Virtu Financial LLC purchased a new position in shares of Senti Biosciences, Inc. (NASDAQ:SNTI) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 13,356 shares of the company’s stock, valued at approximately $47,000. Virtu Financial LLC owned about 0.28% of Senti Biosciences at the end of the most recent reporting period. Institutional investors and hedge funds own 25.73% of the company’s stock.

Senti Biosciences Trading Down 1.6 %

SNTI stock traded down $0.07 during trading on Thursday, hitting $3.99. 21,103 shares of the stock traded hands, compared to its average volume of 62,531. The stock has a market cap of $19.19 million, a price-to-earnings ratio of -0.26 and a beta of 2.46. Senti Biosciences has a one year low of $1.52 and a one year high of $16.94. The company has a 50 day simple moving average of $4.42 and a 200 day simple moving average of $3.19.

Senti Biosciences Company Profile

Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.